BIOTRON LIMITED - Announcements

0.00%

0.3¢

Market Cap $3.318M

Healthcare Biotechnology

Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the... Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The Company also has a portfolio of preclinical antiviral programs.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

BIT	Annual Report to Shareholders	PRICE SENSITIVE	28/08/14	388.98KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/07/14	37.75KB	Share
BIT	BIT225 Reverses HIV-Induced Impairment of the Immune System	PRICE SENSITIVE	23/07/14	792.76KB	Share
BIT	Response to ASX price query	PRICE SENSITIVE	06/06/14	78.98KB	Share
BIT	Presentation to Investors		27/05/14	1.33MB	Share
BIT	BIT225 HCV Trial Update - Thailand	PRICE SENSITIVE	23/05/14	41.72KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/14	73.92KB	Share
BIT	$1.7 Million R&D Tax Incentive Refund	PRICE SENSITIVE	04/04/14	49.09KB	Share
BIT	Letter to Shareholders		31/03/14	240.01KB	Share
BIT	Update on BIT225 HCV Program	PRICE SENSITIVE	11/03/14	54KB	Share
BIT	BIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS	PRICE SENSITIVE	06/03/14	54.55KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/14	116.45KB	Share
BIT	Key USA Patent Allowed for Biotron's BIT225	PRICE SENSITIVE	13/02/14	54.23KB	Share
BIT	Response to ASX query	PRICE SENSITIVE	23/01/14	86.74KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/14	37.71KB	Share
BIT	BIOTRON TO PRESENT AT BIOTECH SHOWCASE 2014		14/01/14	52.89KB	Share
BIT	Presentation of HIV Data at HIV Persistence Meeting	PRICE SENSITIVE	05/12/13	282.82KB	Share
BIT	Independent Research Validates Biotron HCV Drug Candidate	PRICE SENSITIVE	27/11/13	53.94KB	Share
BIT	Ethics Approval for Three Month HCV Trial	PRICE SENSITIVE	21/11/13	59.15KB	Share
BIT	Final Director's Interest Notice		08/11/13	24.57KB	Share
BIT	Results of Meeting		08/11/13	28.75KB	Share
BIT	Presentation to Annual General Meeting		08/11/13	2.88MB	Share
BIT	HCV/HIV Trial Data Presented to International Conference	PRICE SENSITIVE	06/11/13	822.72KB	Share
BIT	Biotron to Present at Australia Biotech Invest 2013		28/10/13	1.65MB	Share
BIT	ANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS	PRICE SENSITIVE	25/10/13	49.49KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/13	37.66KB	Share
BIT	Annual Report and Notice of Annual General Meeting		10/10/13	612.15KB	Share
BIT	Annual Report to shareholders	PRICE SENSITIVE	28/08/13	240.81KB	Share
BIT	Letter to Shareholders		16/08/13	212.96KB	Share
BIT	BIT225 Capsule Formulation Trial Completed	PRICE SENSITIVE	14/08/13	93.96KB	Share
BIT	Patient Enrolment in Phase 2 Co-Infected Study Completed	PRICE SENSITIVE	31/07/13	108.16KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/13	37.72KB	Share
BIT	Presentation of HIV Trial Data to International AIDS Society	PRICE SENSITIVE	01/07/13	2.81MB	Share
BIT	PRESENTATION AT ASIA BIOTECH INVEST 2013 - HONG KONG		05/06/13	1.64MB	Share
BIT	R&D Tax Incentive Refund	PRICE SENSITIVE	31/05/13	33.21KB	Share
BIT	PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY		30/05/13	53.55KB	Share
BIT	Presentation at European Liver Conference		01/05/13	48.68KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	37.71KB	Share
BIT	CEO Presentation at the 2013 BIO International Convention		26/04/13	1.67MB	Share
BIT	Letter to Shareholders		10/04/13	212.75KB	Share
BIT	HIV TRIAL VALIDATES NOVEL DRUG MECHANISM	PRICE SENSITIVE	19/03/13	54.49KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/13	173.99KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	17/01/13	37.7KB	Share
BIT	Biotron Completes Clinical Stage of HIV Clinical Trial	PRICE SENSITIVE	14/12/12	49.29KB	Share
BIT	Results of Meeting		28/11/12	29.33KB	Share
BIT	Chairman's Address and Presentation to the AGM		28/11/12	422.41KB	Share
BIT	Commencement of Three-Month Toxicology Studies For BIT225	PRICE SENSITIVE	27/11/12	48.93KB	Share
BIT	Presentation of BIT225 HCV 48-week data at AASLD Conference	PRICE SENSITIVE	16/11/12	961.96KB	Share
BIT	Key Phase 2 HIV/HCV Trial Commenced	PRICE SENSITIVE	09/11/12	50.25KB	Share
BIT	Presentation to Investors		26/10/12	317.86KB	Share
BIT	Annual Report and Notice of AGM		25/10/12	1.12MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	22/10/12	37.67KB	Share
BIT	Biotron to Present Positive 48 Week Data from HCV Trial	PRICE SENSITIVE	16/10/12	55.68KB	Share
BIT	Shareholder Update		11/10/12	559.71KB	Share
BIT	Change of Director's Interest Notice		12/09/12	38.94KB	Share
BIT	Change of Director's Interest Notice		10/09/12	39.31KB	Share
BIT	App 4E / Full Year Statutory Accounts	PRICE SENSITIVE	31/08/12	467.75KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/12	78.17KB	Share
BIT	Change of Director's Interest Notice		15/06/12	110.63KB	Share
BIT	Shareholder Update		04/05/12	239.29KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	20/04/12	49.11KB	Share
BIT	Appendix 3B		03/04/12	108.21KB	Share
BIT	Appointment of Directors		07/03/12	32.45KB	Share
BIT	Option Expiry Notice		29/02/12	71.92KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/12	144.7KB	Share
BIT	CEO Presentation at International Investor Conference		15/02/12	383.66KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/12	49.12KB	Share
BIT	ASX price query and response	PRICE SENSITIVE	16/01/12	72.21KB	Share
BIT	Presentation to Investors		12/01/12	374.97KB	Share
BIT	Change of Director's Interest Notice		09/01/12	103.13KB	Share
BIT	Exercise of Options Raises $8.0 Million	PRICE SENSITIVE	06/01/12	93.74KB	Share
BIT	Change of Director's Interest Notice		09/12/11	48.95KB	Share
BIT	Letter to Security Holders		09/12/11	219.19KB	Share
BIT	Change of Director's Interest Notice		09/12/11	48.92KB	Share
BIT	Change of Director's Interest Notice		08/12/11	48.98KB	Share
BIT	POSITIVE 3 MONTH DATA FOR BIT225 - 87% VIRUS FREE	PRICE SENSITIVE	07/12/11	71.16KB	Share
BIT	Response to ASX query		02/12/11	57.62KB	Share
BIT	Option Expiry Notice		30/11/11	57.02KB	Share
BIT	Change of Director's Interest Notice		30/11/11	49.5KB	Share
BIT	Appendix 3B		25/11/11	60.77KB	Share
BIT	Results of Meeting		22/11/11	24.16KB	Share
BIT	Presentation to Annual General Meeting		22/11/11	245.17KB	Share
BIT	Final Director's Interest Notice		21/11/11	27.23KB	Share
BIT	Dr. Michael Hirshorn		18/11/11	20.67KB	Share
BIT	Biotron Presentation at International Hepatitis Conference		18/11/11	38.72KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/11	49.09KB	Share
BIT	Annual Report and Notice of Annual General Meeting		24/10/11	645.8KB	Share
BIT	Letter to Shareholders		24/10/11	220KB	Share
BIT	Appendix 3B		24/10/11	300.67KB	Share
BIT	Presentation to Investors		19/10/11	167.77KB	Share
BIT	Boardroom Radio Broadcast		11/10/11	20.58KB	Share
BIT	HEPATITIS C PHASE 2A TRIAL POSITIVE RESULTS	PRICE SENSITIVE	10/10/11	163.28KB	Share
BIT	Trading Halt	PRICE SENSITIVE	07/10/11	52.95KB	Share
BIT	Landmark HIV Trial Underway	PRICE SENSITIVE	29/09/11	23.57KB	Share
BIT	Year End Accounts and Preliminary Final Report	PRICE SENSITIVE	30/08/11	448.31KB	Share
BIT	Letter to Shareholders		29/07/11	215.66KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/11	49.14KB	Share
BIT	Final Patient Dosed in Landmark Hepatitis C Trial		07/07/11	78.78KB	Share
BIT	CEO Presentation at BIO2011 in Washington DC		01/07/11	1.78MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	19/04/11	49.12KB	Share

BIT Annual Report to Shareholders
28/08/14	PRICE SENSITIVE	388.98KB	Share
BIT Appendix 4C - quarterly
24/07/14	PRICE SENSITIVE	37.75KB	Share
BIT BIT225 Reverses HIV-Induced Impairment of the Immune System
23/07/14	PRICE SENSITIVE	792.76KB	Share
BITResponse to ASX price query
06/06/14	PRICE SENSITIVE	78.98KB	Share
BITPresentation to Investors
27/05/14		1.33MB	Share
BITBIT225 HCV Trial Update - Thailand
23/05/14	PRICE SENSITIVE	41.72KB	Share
BITAppendix 4C - quarterly
24/04/14	PRICE SENSITIVE	73.92KB	Share
BIT$1.7 Million R&D Tax Incentive Refund
04/04/14	PRICE SENSITIVE	49.09KB	Share
BITLetter to Shareholders
31/03/14		240.01KB	Share
BITUpdate on BIT225 HCV Program
11/03/14	PRICE SENSITIVE	54KB	Share
BITBIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS
06/03/14	PRICE SENSITIVE	54.55KB	Share
BITHalf Yearly Report and Accounts
21/02/14	PRICE SENSITIVE	116.45KB	Share
BITKey USA Patent Allowed for Biotron's BIT225
13/02/14	PRICE SENSITIVE	54.23KB	Share
BITResponse to ASX query
23/01/14	PRICE SENSITIVE	86.74KB	Share
BITAppendix 4C - quarterly
21/01/14	PRICE SENSITIVE	37.71KB	Share
BITBIOTRON TO PRESENT AT BIOTECH SHOWCASE 2014
14/01/14		52.89KB	Share
BITPresentation of HIV Data at HIV Persistence Meeting
05/12/13	PRICE SENSITIVE	282.82KB	Share
BITIndependent Research Validates Biotron HCV Drug Candidate
27/11/13	PRICE SENSITIVE	53.94KB	Share
BITEthics Approval for Three Month HCV Trial
21/11/13	PRICE SENSITIVE	59.15KB	Share
BITFinal Director's Interest Notice
08/11/13		24.57KB	Share
BITResults of Meeting
08/11/13		28.75KB	Share
BITPresentation to Annual General Meeting
08/11/13		2.88MB	Share
BITHCV/HIV Trial Data Presented to International Conference
06/11/13	PRICE SENSITIVE	822.72KB	Share
BITBiotron to Present at Australia Biotech Invest 2013
28/10/13		1.65MB	Share
BITANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS
25/10/13	PRICE SENSITIVE	49.49KB	Share
BITAppendix 4C - quarterly
21/10/13	PRICE SENSITIVE	37.66KB	Share
BITAnnual Report and Notice of Annual General Meeting
10/10/13		612.15KB	Share
BITAnnual Report to shareholders
28/08/13	PRICE SENSITIVE	240.81KB	Share
BITLetter to Shareholders
16/08/13		212.96KB	Share
BITBIT225 Capsule Formulation Trial Completed
14/08/13	PRICE SENSITIVE	93.96KB	Share
BITPatient Enrolment in Phase 2 Co-Infected Study Completed
31/07/13	PRICE SENSITIVE	108.16KB	Share
BITAppendix 4C - quarterly
26/07/13	PRICE SENSITIVE	37.72KB	Share
BITPresentation of HIV Trial Data to International AIDS Society
01/07/13	PRICE SENSITIVE	2.81MB	Share
BITPRESENTATION AT ASIA BIOTECH INVEST 2013 - HONG KONG
05/06/13		1.64MB	Share
BITR&D Tax Incentive Refund
31/05/13	PRICE SENSITIVE	33.21KB	Share
BITPRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY
30/05/13		53.55KB	Share
BITPresentation at European Liver Conference
01/05/13		48.68KB	Share
BITAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	37.71KB	Share
BITCEO Presentation at the 2013 BIO International Convention
26/04/13		1.67MB	Share
BITLetter to Shareholders
10/04/13		212.75KB	Share
BITHIV TRIAL VALIDATES NOVEL DRUG MECHANISM
19/03/13	PRICE SENSITIVE	54.49KB	Share
BITHalf Yearly Report and Accounts
27/02/13	PRICE SENSITIVE	173.99KB	Share
BITAppendix 4C - quarterly
17/01/13	PRICE SENSITIVE	37.7KB	Share
BITBiotron Completes Clinical Stage of HIV Clinical Trial
14/12/12	PRICE SENSITIVE	49.29KB	Share
BITResults of Meeting
28/11/12		29.33KB	Share
BITChairman's Address and Presentation to the AGM
28/11/12		422.41KB	Share
BITCommencement of Three-Month Toxicology Studies For BIT225
27/11/12	PRICE SENSITIVE	48.93KB	Share
BITPresentation of BIT225 HCV 48-week data at AASLD Conference
16/11/12	PRICE SENSITIVE	961.96KB	Share
BITKey Phase 2 HIV/HCV Trial Commenced
09/11/12	PRICE SENSITIVE	50.25KB	Share
BITPresentation to Investors
26/10/12		317.86KB	Share
BITAnnual Report and Notice of AGM
25/10/12		1.12MB	Share
BITAppendix 4C - quarterly
22/10/12	PRICE SENSITIVE	37.67KB	Share
BITBiotron to Present Positive 48 Week Data from HCV Trial
16/10/12	PRICE SENSITIVE	55.68KB	Share
BITShareholder Update
11/10/12		559.71KB	Share
BITChange of Director's Interest Notice
12/09/12		38.94KB	Share
BITChange of Director's Interest Notice
10/09/12		39.31KB	Share
BITApp 4E / Full Year Statutory Accounts
31/08/12	PRICE SENSITIVE	467.75KB	Share
BITAppendix 4C - quarterly
27/07/12	PRICE SENSITIVE	78.17KB	Share
BITChange of Director's Interest Notice
15/06/12		110.63KB	Share
BITShareholder Update
04/05/12		239.29KB	Share
BITAppendix 4C - quarterly
20/04/12	PRICE SENSITIVE	49.11KB	Share
BITAppendix 3B
03/04/12		108.21KB	Share
BITAppointment of Directors
07/03/12		32.45KB	Share
BITOption Expiry Notice
29/02/12		71.92KB	Share
BITHalf Yearly Report and Accounts
28/02/12	PRICE SENSITIVE	144.7KB	Share
BITCEO Presentation at International Investor Conference
15/02/12		383.66KB	Share
BITAppendix 4C - quarterly
24/01/12	PRICE SENSITIVE	49.12KB	Share
BITASX price query and response
16/01/12	PRICE SENSITIVE	72.21KB	Share
BITPresentation to Investors
12/01/12		374.97KB	Share
BITChange of Director's Interest Notice
09/01/12		103.13KB	Share
BITExercise of Options Raises $8.0 Million
06/01/12	PRICE SENSITIVE	93.74KB	Share
BITChange of Director's Interest Notice
09/12/11		48.95KB	Share
BITLetter to Security Holders
09/12/11		219.19KB	Share
BITChange of Director's Interest Notice
09/12/11		48.92KB	Share
BITChange of Director's Interest Notice
08/12/11		48.98KB	Share
BITPOSITIVE 3 MONTH DATA FOR BIT225 - 87% VIRUS FREE
07/12/11	PRICE SENSITIVE	71.16KB	Share
BITResponse to ASX query
02/12/11		57.62KB	Share
BITOption Expiry Notice
30/11/11		57.02KB	Share
BITChange of Director's Interest Notice
30/11/11		49.5KB	Share
BITAppendix 3B
25/11/11		60.77KB	Share
BITResults of Meeting
22/11/11		24.16KB	Share
BITPresentation to Annual General Meeting
22/11/11		245.17KB	Share
BITFinal Director's Interest Notice
21/11/11		27.23KB	Share
BITDr. Michael Hirshorn
18/11/11		20.67KB	Share
BITBiotron Presentation at International Hepatitis Conference
18/11/11		38.72KB	Share
BITAppendix 4C - quarterly
27/10/11	PRICE SENSITIVE	49.09KB	Share
BITAnnual Report and Notice of Annual General Meeting
24/10/11		645.8KB	Share
BITLetter to Shareholders
24/10/11		220KB	Share
BITAppendix 3B
24/10/11		300.67KB	Share
BITPresentation to Investors
19/10/11		167.77KB	Share
BITBoardroom Radio Broadcast
11/10/11		20.58KB	Share
BITHEPATITIS C PHASE 2A TRIAL POSITIVE RESULTS
10/10/11	PRICE SENSITIVE	163.28KB	Share
BITTrading Halt
07/10/11	PRICE SENSITIVE	52.95KB	Share
BITLandmark HIV Trial Underway
29/09/11	PRICE SENSITIVE	23.57KB	Share
BITYear End Accounts and Preliminary Final Report
30/08/11	PRICE SENSITIVE	448.31KB	Share
BITLetter to Shareholders
29/07/11		215.66KB	Share
BITAppendix 4C - quarterly
27/07/11	PRICE SENSITIVE	49.14KB	Share
BITFinal Patient Dosed in Landmark Hepatitis C Trial
07/07/11		78.78KB	Share
BITCEO Presentation at BIO2011 in Washington DC
01/07/11		1.78MB	Share
BITAppendix 4C - quarterly
19/04/11	PRICE SENSITIVE	49.12KB	Share

REFRESH

First 2 3 4 5

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $3.318M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.3¢	$2.268K	907.3K

Buyers (Bids)

No.	Vol.	Price($)
44	34518630	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	15608554	19

View Market Depth

No.	Vol.	Price($)
44	34518630	0.002
34	94302000	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	15608554	19
0.004	16987080	16
0.005	6690600	5
0.006	1200000	2
0.007	572733	2

Last trade - 14.43pm 30/07/2025 (20 minute delay)


Last 0.3¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.3¢	0.3¢	0.3¢	6000
Last updated 14.43pm 30/07/2025 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available